Sylvester Cancer Clinical Trials

20160793 - Barredo Julio

Investigator: Julio Barredo Email		Coordinator: Eva Pavicic +1 (305) 2437846
IRB: 20160793		SDG: Pediatric Cancer
Disease Site(s): Soft Tissue
Sponsor: Moffitt Cancer Center		Enrolling Sites: JMH Sylvester

Title: Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Eligibility Criteria - NCT02945800 *This information has been extracted from " www.clinicaltrials.gov"

ANBL1232 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20161103		SDG: Pediatric Cancer
Disease Site(s): Brain and Nervous System
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
Eligibility Criteria - NCT02176967 *This information has been extracted from " www.clinicaltrials.gov"

ARST1431 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20170069		SDG: Pediatric Cancer
Disease Site(s): Soft Tissue
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Eligibility Criteria - NCT02567435 *This information has been extracted from " www.clinicaltrials.gov"

AGCT1531 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20170605		SDG: Pediatric Cancer
Disease Site(s): Other Female Genital,Other Male Genital,Ovary
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Eligibility Criteria - NCT03067181 *This information has been extracted from " www.clinicaltrials.gov"

AALL1631 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20170840		SDG: Pediatric Cancer
Disease Site(s): Lymphoid Leukemia
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: AALL1631:International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.
Eligibility Criteria - NCT03007147 *This information has been extracted from " www.clinicaltrials.gov"

ADVL1521 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20180133		SDG: Pediatric Cancer
Disease Site(s): Myeloid and Monocytic Leukemia
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: ADVL1521: A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Eligibility Criteria - NCT03190915 *This information has been extracted from " www.clinicaltrials.gov"

ANBL1531 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator:
IRB: 20180624		SDG: Pediatric Cancer
Disease Site(s): Brain and Nervous System
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: ANBL1531 : A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)) (IND# 134379)
Eligibility Criteria - NCT03126916 *This information has been extracted from " www.clinicaltrials.gov"

AHEP1531 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator:
IRB: 20180800		SDG: Pediatric Cancer
Disease Site(s): Liver
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Eligibility Criteria - NCT03533582 *This information has been extracted from " www.clinicaltrials.gov"

19487 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Eva Pavicic +1 (305) 2437846
IRB: 20181082		SDG: Pediatric Cancer
Disease Site(s): Bones and Joints
Sponsor: Moffitt Cancer Center		Enrolling Sites: JMH Sylvester

Title: 19487: A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Eligibility Criteria - NCT03628209 *This information has been extracted from " www.clinicaltrials.gov"

T2017-002 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Eva Pavicic +1 (305) 2437846
IRB: 20190180		SDG: Pediatric Cancer
Disease Site(s): Lymphoid Leukemia
Sponsor: THERAPEUTIC ADVANCES IN CHILDHOOD LEUKEMIA		Enrolling Sites: JMH Sylvester

Title: T2017-002 : A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730
Eligibility Criteria - NCT03817320 *This information has been extracted from " www.clinicaltrials.gov"

ACNS1422 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator:
IRB: 20190523		SDG: Pediatric Cancer
Disease Site(s): Brain and Nervous System
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Eligibility Criteria - NCT02724579 *This information has been extracted from " www.clinicaltrials.gov"

AGCT1532 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20190525		SDG: Pediatric Cancer
Disease Site(s): Other Urinary,Prostate
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: Phase 3 Accelerated BEP: A Randomised Phase 3 Trial Of Accelerated Versus Standard BEP Chemotherapy For Patients With Intermediate And Poor-Risk Metastatic Germ Cell Tumours
Eligibility Criteria - NCT02582697 *This information has been extracted from " www.clinicaltrials.gov"

20191014 - Barredo Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20191014		SDG: Pediatric Cancer
Disease Site(s): Lymphoid Leukemia,Non-Hodgkin Lymphoma
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Eligibility Criteria - NCT03914625 *This information has been extracted from " www.clinicaltrials.gov"

20191015 - Barredo Julio

Investigator: Julio Barredo Email		Coordinator:
IRB: 20191015		SDG: Pediatric Cancer
Disease Site(s): Myeloid and Monocytic Leukemia
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Eligibility Criteria - NCT03817398 *This information has been extracted from " www.clinicaltrials.gov"

20191078 - Barredo Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20191078		SDG: Pediatric Cancer
Disease Site(s): Brain and Nervous System
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Eligibility Criteria - NCT03919071 *This information has been extracted from " www.clinicaltrials.gov"

LOXO-101 - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20191079		SDG: Pediatric Cancer
Disease Site(s): Leukemia, Other
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Eligibility Criteria - NCT03834961 *This information has been extracted from " www.clinicaltrials.gov"

20191175 - Barredo Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20191175		SDG: Pediatric Cancer
Disease Site(s): Leukemia, Other,Lymphoid Leukemia
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Eligibility Criteria - NCT03959085 *This information has been extracted from " www.clinicaltrials.gov"

APEC1621A - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator:
IRB: 20191246		SDG: Pediatric Cancer
Disease Site(s): Non-Hodgkin Lymphoma
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Eligibility Criteria - NCT03213704 *This information has been extracted from " www.clinicaltrials.gov"

APEC1621F - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20191254		SDG: Pediatric Cancer
Disease Site(s): Non-Hodgkin Lymphoma
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Eligibility Criteria - NCT03213652 *This information has been extracted from " www.clinicaltrials.gov"

APEC1621l - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20191257		SDG: Pediatric Cancer
Disease Site(s): Non-Hodgkin Lymphoma
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Eligibility Criteria - NCT03526250 *This information has been extracted from " www.clinicaltrials.gov"

APEC1621SC - Barredo, Julio

Investigator: Julio Barredo Email		Coordinator: Nuria Garantiva +1 (786) 2743477
IRB: 20191259		SDG: Pediatric Cancer
Disease Site(s): Non-Hodgkin Lymphoma
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Eligibility Criteria - NCT03155620 *This information has been extracted from " www.clinicaltrials.gov"

20201135 - Barredo Julio

Investigator: Julio Barredo Email		Coordinator:
IRB: 20201135		SDG: Pediatric Cancer
Disease Site(s):
Sponsor: COG		Enrolling Sites: JMH Sylvester

Title: A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Eligibility Criteria - NCT04293562 *This information has been extracted from " www.clinicaltrials.gov"

20210237 - Barredo Julio

Investigator: Julio Barredo Email		Coordinator:
IRB: 20210237		SDG: Pediatric Cancer
Disease Site(s): Kidney
Sponsor: COG		Enrolling Sites: Sylvester

Title: A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Eligibility Criteria - NCT03595124 *This information has been extracted from " www.clinicaltrials.gov"

20210234 - Dhir Aditi

Investigator: Aditi Dhir Email		Coordinator: Eva Pavicic +1 (305) 2437846
IRB: 20210234		SDG: Pediatric Cancer
Disease Site(s): Soft Tissue
Sponsor: Moffitt Cancer Center		Enrolling Sites: Sylvester

Title: Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Eligibility Criteria - NCT04388839 *This information has been extracted from " www.clinicaltrials.gov"

20160415 - St. George Sara

Investigator: Sara St. George Email		Coordinator:
IRB: 20160415		SDG: Population Sciences
Disease Site(s): Multiple
Sponsor: NHLBI		Enrolling Sites: Community Clinics JMH Sylvester UMH

Title: St. George K01: Family-based eHealth Obesity Prevention Intervention for Hispanic Adolescents
Eligibility Criteria - NCT03986190 *This information has been extracted from " www.clinicaltrials.gov"

KTE-C19-104 - Ziga, Edward

Investigator: Edward Ziga Email		Coordinator: Eva Pavicic +1 (305) 2437846
IRB: 20160129		SDG: Pediatric Cancer
Disease Site(s): Lymphoid Leukemia
Sponsor: Kite		Enrolling Sites: JMH Sylvester

Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)
Eligibility Criteria - NCT02625480 *This information has been extracted from " www.clinicaltrials.gov"

Back to Top